Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA budget mark-up

This article was originally published in The Gray Sheet

Executive Summary

Agency's fiscal year 1999 budget will be marked up by the Senate Appropriations/Agriculture Subcommittee June 9 and by the House Appropriations/Agriculture Subcommitee on June 10. FDA's proposed budget, which calls for flat funding compared to FY 1998 for the Center for Devices and Radiological Health, was reviewed by the House Subcommittee Feb. 25 ("The Gray Sheet" March 2, p. 10) and the Senate March 31 ("The Gray Sheet" April 6, p. 5)...

You may also be interested in...



Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics

Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.

EU Regulatory Roundup, March 2020: MDR Delay And Unprecedented COVID-19 Measures

Non-CE-marked products on the EU market, virtual notified body audits, free standards and the Commission bid to pause the MDR. March has seen unprecedented developments as COVID-19 has railroaded through the sector decimating regulatory rules and plans.

Jubilant Sees No Material Impact From Coronavirus-Led Plant Closure, For Now

Jubilant Life Sciences anticipates continued strong demand despite temporary logistics blips in India and expects to resume operations at its Nanjangud plant, currently shut down due to a few COVID-19 cases among employees, by mid-April. It is also evaluating the feasibility of manufacturing some of the APIs recently incentivized by the Indian government.

UsernamePublicRestriction

Register

MT010149

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel